drugset / Trial / NCT03804411

Prognostic Predictors of Response to Hypoglycemic Therapy

NCT03804411 ↗

RandomizedParallel-groupSingle-blindBasic science

Summary

This is a randomized controlled trial aimed to determine highly specific personified predictors of response to the therapy by different groups of hypoglycemic drugs (SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, sulfonylureas) in patients with type 2 diabetes mellitus, develop an algorithm of personalized therapy based on them, design an organizational and methodological model for prevention of the cardiovascular complications, and create an automated decision-making system for therapy selection to reduce the incidence of cardiovascular events and related adverse outcomes compared to the traditional approach. This is an interventional, randomized controlled trial, open-label study.

Timeline

Start
2017-08-01
Primary completion
2020-03
Completion
2020-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg —
Subject Empagliflozin Small molecule 10 mg —
Subject Exenatide Peptide 20 ug —
Subject Gliclazide Small molecule — —
Subject Glimepiride Small molecule — —
Subject Liraglutide Peptide 1.2 mg —
Subject Liraglutide Peptide 1.8 mg —
Subject Sitagliptin Small molecule 100 mg —
Subject Vildagliptin Other / unclassified 100 mg —